Pulse Biosciences Quarterly Cash Flow Statement
NASDAQ: PLSEHealth CareMedical/Dental InstrumentsUSD
53.81+3.83 (+7.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pulse Biosciences free cash flow
In the quarter ended Jun 30, 2026, Pulse Biosciences generated -$18.7 million of operating cash flow and spent $90,000 on capital expenditures. That left free cash flow of -$18.8 million, a free-cash-flow margin of -4331.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Pulse Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -24.66M | -18.58M | -17.43M | -19.39M | -19.17M | -16.80M | -19.39M | -12.68M | -11.38M | -10.14M | -11.93M | -10.57M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 88.00K | 88.00K | 93.00K | 100.00K | 100.00K | 117.00K | 121.00K | 100.00K | 100.00K | 132.00K | 138.00K | 100.00K |
| Stock-Based Compensation | 4.97M | 1.91M | 4.97M | 5.62M | 5.19M | 5.68M | 6.79M | 2.98M | 2.05M | 1.76M | 3.34M | 1.80M |
| Change in Working Capital | 771.00K | 1.54M | -2.52M | 579.00K | 948.00K | -2.64M | 3.24M | 422.00K | 660.00K | -1.66M | 1.52M | -250.00K |
| Operating Cash Flow | -18.71M | -14.60M | -14.76M | -13.04M | -12.81M | -13.52M | -9.14M | -9.02M | -8.39M | -9.78M | -6.78M | -10.49M |
| Capital Expenditures | -90.00K | -33.00K | -105.00K | -62.00K | -103.00K | -45.00K | -53.00K | -38.00K | -29.00K | -5.00K | -43.00K | -23.00K |
| Investing Cash Flow | -90.00K | -33.00K | -105.00K | -62.00K | -123.00K | -45.00K | -53.00K | -38.00K | -29.00K | -5.00K | -43.00K | -23.00K |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Financing Cash Flow | 52.10M | 2.21M | 381.00K | 1.97M | 0 | 14.81M | 48.20M | 61.90M | -265.00K | 305.00K | 804.00K | 2.15M |
| Net Change in Cash | 33.30M | -12.42M | -14.48M | -11.13M | -12.93M | 1.24M | 39.01M | 52.84M | -8.69M | -9.48M | -6.02M | -8.36M |
| Free Cash Flow | -18.80M | -14.63M | -14.86M | -13.10M | -12.91M | -13.57M | -9.20M | -9.06M | -8.42M | -9.79M | -6.83M | -10.51M |
This table shows 12 quarterly periods of Pulse Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PLSE's reporting calendar. What is a cash flow statement?